To access the live call by phone, dial 719-325-4845; the conference ID
is 8195001. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®,
in other clinical-stage ImmunoGen product candidates, and in programs in
development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
Courtney O'Konek, 781-895-0158
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media